Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 2:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Post-acute COVID-19 Syndrome Clear all
Not listed Not applicable Interventional Accepts healthy volunteers

(CBDRA60) to Prevent or Reduce Symptoms of COVID-19 and Prevention of Post-Acute Sequelae of SARS-CoV-2 Infection PASC

NCT04777981
View directory record Official record
Conditions
COVID-19, SAR
Interventions
CBDRA60 supplement, Placebo
Dietary Supplement
Lead sponsor
Anewsha Therapeutics Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Hanover, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 21, 2022 · Synced Jun 26, 2026, 2:35 AM EDT
Recruiting Phase 2 Interventional

Magnetic Resonance Analysis of Neural Inflammatory Factors and External Stimulation

NCT06940609
View directory record Official record
Conditions
Long COVID, Long COVID Syndrome, Long COVID-19 Syndrome, PASC, PASC Post Acute Sequelae of COVID 19
Interventions
accelerated intermittent theta burst stimulation
Device
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Jun 26, 2026, 2:35 AM EDT
Completed No phase listed Observational

Impact of Monoclonal Antibody Treatment on Post-Acute COVID-19 Syndrome

NCT05013723
View directory record Official record
Conditions
Post-acute COVID-19 (PACS), or "long COVID" Syndrome
Interventions
Surveys
Other
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Nov 6, 2024 · Synced Jun 26, 2026, 2:35 AM EDT
Not listed No phase listed Observational

Effect of Apollo Wearable on Long COVID-19 Symptoms.

NCT06097442
View directory record Official record
Conditions
Post-acute Sequelae of SARS-COV-2 Infection
Interventions
Not listed
Lead sponsor
The Board of Medicine
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 26, 2023 · Synced Jun 26, 2026, 2:35 AM EDT
Withdrawn Phase 2 Interventional

A Study of Amantadine for Cognitive Dysfunction in Patients With Long-Covid

NCT06234462
View directory record Official record
Conditions
Long COVID, Post-Acute COVID-19 Syndrome
Interventions
Amantadine, Physical, Occupational, Speech Therapy, Provider Counseling, Medications for symptoms management
Drug · Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
20 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2025 · Synced Jun 26, 2026, 2:35 AM EDT
Completed Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP)

NCT04328961
View directory record Official record
Conditions
COVID-19, Corona Virus Infection, SARS (Severe Acute Respiratory Syndrome), SARS-CoV-2
Interventions
Hydroxychloroquine Sulfate, Ascorbic Acid
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 80 Years
Enrollment
943 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
8
States / cities
Los Angeles, California • New Orleans, Louisiana • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2021 · Synced Jun 26, 2026, 2:35 AM EDT
Recruiting Phase 3 Interventional

Long Covid (LC)-REVITALIZE - A Long Covid Repurposed Drug Study

NCT06928272
View directory record Official record
Conditions
Long COVID
Interventions
Pirfenidone, Placebo for pirfenidone, Upadacitinib, Placebo for upadacitinib
Drug
Lead sponsor
Douglas D. Fraser
Other
Eligibility
18 Years to 65 Years
Enrollment
348 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Jun 26, 2026, 2:35 AM EDT
Recruiting Phase 3 Interventional

Low Dose Sirolimus in People With Post-Acute Sequelae of COVID-19 (PASC) Long COVID-19

NCT06960928
View directory record Official record
Conditions
Long COVID-19
Interventions
Low-dose sirolimus, Placebo
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Jun 26, 2026, 2:35 AM EDT
Not yet recruiting Phase 2Phase 3 Interventional

A Multi-Center, Individually-Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Superiority Trial to Evaluate the Efficacy of the Combination of Maraviroc and Atorvastatin for the Treatment of Subjects With Long COVID

NCT06974084
View directory record Official record
Conditions
Long COVID
Interventions
Maraviroc (MVC), Atorvastatin, 10mg, 20mg, 40mg, Placebo, Maraviroc, Placebo, Atorvastatin
Drug
Lead sponsor
HealthBio, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Jun 26, 2026, 2:35 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Covid-19 Virtual Recovery Study

NCT04950725
View directory record Official record
Conditions
Covid19
Interventions
Strength RMT, Strength RMT and nasal breathing, Endurance RMT, Endurance RMT and nasal breathing, Low dose RMT
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
2,268 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced Jun 26, 2026, 2:35 AM EDT
Recruiting Phase 2 Interventional

LIFT: Life Improvement Trial

NCT06366724
View directory record Official record
Conditions
ME/CFS, Long COVID, PASC
Interventions
Pyridostigmine, Low-Dose Naltrexone, Placebo
Drug · Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 70 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Jun 26, 2026, 2:35 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Cognitive-Sensorimotor Function in Long-COVID

NCT06850350
View directory record Official record
Conditions
Post-acute Sequelae of SARS-CoV-2 Infection
Interventions
Not listed
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Jun 26, 2026, 2:35 AM EDT
Enrolling by invitation No phase listed Observational

Evaluating the Response of the Immune System of People with Long COVID (post SARS-CoV-2)

NCT05131594
View directory record Official record
Conditions
COVID-19
Interventions
Not listed
Lead sponsor
Huntington Memorial Hospital
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Jun 26, 2026, 2:35 AM EDT
Recruiting Phase 2 Interventional

A Study to Examine Anktiva for the Treatment of COVID-19.

NCT07123727
View directory record Official record
Conditions
Long COVID, Long COVID Syndrome, Long Covid 19
Interventions
Anktiva
Drug
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
El Segundo, California
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Jun 26, 2026, 2:35 AM EDT
Recruiting Not applicable Interventional

Mind Body Intervention for Long COVID-19

NCT06045338
View directory record Official record
Conditions
Long COVID, Post-Acute Sequelae of COVID-19, COVID Long-Haul
Interventions
Mind Body Intervention #1
Behavioral
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Jun 26, 2026, 2:35 AM EDT
Terminated Phase 3 Interventional Results available

Treatment of Long CoronaVirus Disease (COVID) (TLC) Feasibility Trial

NCT05946551
View directory record Official record
Conditions
COVID-19
Interventions
Cetirizine, Famotidine, Cetirizine Placebo, Famotidine Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
4
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Jun 26, 2026, 2:35 AM EDT
Not listed Phase 4 Interventional

Ivabradine for Long-Term Effects of COVID-19 With POTS Cohort

NCT05481177
View directory record Official record
Conditions
Long Haul COVID, Postural Orthostatic Tachycardia Syndrome
Interventions
Ivabradine
Drug
Lead sponsor
Uniformed Services University of the Health Sciences
Federal
Eligibility
18 Years to 80 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Jun 26, 2026, 2:35 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Open-label, Post-marketing, Prospective Study to Assess Impact of COVID-19 on Cognitive Function in Patients

NCT04950673
View directory record Official record
Conditions
Cognitive Decline, Cognitive Dysfunction, Brain Health, Post CoV-2 Syndrome, COVID Long-Haul
Interventions
Cognivue
Device
Lead sponsor
Cognivue, Inc.
Industry
Eligibility
18 Years to 95 Years
Enrollment
1,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
4
States / cities
Irvine, California • Visalia, California • Boca Raton, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2022 · Synced Jun 26, 2026, 2:35 AM EDT
Terminated No phase listed Observational

Low-Level Laser Therapy Treatment of Lung Inflammation in Post-COVID-19 Recovery

NCT05258617
View directory record Official record
Conditions
COVID-19, Acute Respiratory Distress Syndrome
Interventions
LLLT Photobiomodulation
Device
Lead sponsor
Ward Photonics LLC
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
7
States / cities
Berkeley, California • Los Angeles, California • Santa Monica, California + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2022 · Synced Jun 26, 2026, 2:35 AM EDT
Available No phase listed Expanded access

Expanded Access Use of Human Umbilical Cord Blood (REGENECYTE) Infusion in Patients With Chronic Fatigue of Post-COVID Condition

NCT07332338
View directory record Official record
Conditions
Post-COVID-19 Condition, Post-COVID Condition, Post-COVID Syndrome, Long COVID, Chronic Fatigue, Chronic Fatigue Symptoms, Fatigue Post Viral
Interventions
REGENECYTE®
Biological
Lead sponsor
StemCyte, Inc.
Industry
Eligibility
18 Years and older
U.S. locations
2
States / cities
Miami, Florida • Miami Lakes, Florida
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Jun 26, 2026, 2:35 AM EDT
Recruiting Phase 1 Interventional

Kisspeptin to Quantify GnRH Neuronal Function in Health and Disease

NCT07224490
View directory record Official record
Conditions
Reproductive Disorder, Neurodegeneration, SARS-CoV 2, Long COVID
Interventions
Kisspeptin 112-121
Drug
Lead sponsor
Stephanie B. Seminara, MD
Other
Eligibility
18 Years to 60 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Jun 26, 2026, 2:35 AM EDT
Completed Phase 3 Interventional Results available

Post-exposure Prophylaxis / Preemptive Therapy for SARS-Coronavirus-2

NCT04308668
View directory record Official record
Conditions
Corona Virus Infection, Acute Respiratory Distress Syndrome, SARS-CoV Infection, Coronavirus, Coronavirus Infections
Interventions
Hydroxychloroquine, Placebo
Drug · Other
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
1,312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
2
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Jun 26, 2026, 2:35 AM EDT
Completed Phase 2 Interventional Results available

RECOVER-VITAL: Platform Protocol, Appendix to Measure the Effects of Paxlovid on Long COVID Symptoms

NCT05965726
View directory record Official record
Conditions
Long COVID-19, Long COVID
Interventions
Paxlovid, Ritonavir, Nirmatrelvir-matching placebo
Drug
Lead sponsor
Kanecia Obie Zimmerman
Other
Eligibility
18 Years and older
Enrollment
964 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Jun 26, 2026, 2:35 AM EDT
Active, not recruiting Phase 2 Interventional

Sodium Citrate in Smell Retraining for People With Post-COVID-19 Olfactory Dysfunction

NCT06204432
View directory record Official record
Conditions
Long Haul COVID-19, Post-Acute COVID-19 Syndrome, Anosmia, Olfaction Disorders
Interventions
Sodium Citrate, Normal Saline, Olfactory Training Kit - "The Olfactory Kit, by AdvancedRx"
Drug · Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Jun 26, 2026, 2:35 AM EDT